


PRODUCT INFORMATION



Endoxifen

Item No. 16022

CAS Registry No.: 112093-28-4
Formal Name: 4-[(1Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
Synonyms: N-Desmethyl-4-Hydroxytamoxifen, 4-Hydroxy-N-Desmethyltamoxifen
MF: C₂₅H₂₇NO₂
FW: 373.5
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 245, 286 nm



Laboratory Procedures

For long term storage, we suggest that endoxifen be stored as supplied at -20°C. It should be stable for at least two years.

Endoxifen is supplied as a crystalline solid. A stock solution may be made by dissolving the endoxifen in the solvent of choice. Endoxifen is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of endoxifen in these solvents is approximately 20, 2, and 20 mg/ml, respectively.

Endoxifen is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, endoxifen should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Endoxifen has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tamoxifen (TMX; Item No. 13258) is a selective estrogen receptor (ER) modulator used as adjuvant therapy for estrogen-dependent breast cancer.¹ Endoxifen is an active metabolite of TMX, produced by the sequential action of cytochrome P450 (CYP) isoforms, including CYP2D6.²⁻⁴ It is a strong anti-estrogen, as it has an approximately 100-fold greater affinity for ERs than TMX.² As the efficient conversion of TMX to endoxifen depends on CYP2D6, polymorphisms in this CYP isoform can impact the effectiveness of TMX treatment.²⁻⁴

References

1. Clarke, M., Collins, R., Davies, C., *et al.* Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet* **351**, 1451-1467 (1998).
2. Brauch, H., Mürdter, T.E., Eichelbaum, M., *et al.* Pharmacogenomics of tamoxifen therapy. *Clin. Chem.* **55(10)**, 1770-1782 (2009).
3. Mugundu, G.M., Sallans, L., Guo, Y., *et al.* Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. *Drug Metab. Dispos.* **40(2)**, 389-396 (2012).
4. Markopoulos, C., Kykalos, S., and Mantas, D. Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. *World J. Clin. Oncol.* **5(3)**, 374-381 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/14/2015

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM